4 x
NAG:
2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.10:
3
residues within 4Å:
Chain A:
W.149,
V.241,
N.243
4 PLIP interactions:
4 interactions with chain A
Water bridges:
A:N.243,
A:N.243,
A:N.243,
A:N.243
NAG.13:
4
residues within 4Å:
Chain B:
E.35,
N.36,
N.37,
N.54
2 PLIP interactions:
2 interactions with chain B
Hydrogen bonds:
B:N.37,
B:N.54
NAG.14:
3
residues within 4Å:
Chain B:
R.109,
I.110,
N.112
4 PLIP interactions:
4 interactions with chain B
Hydrophobic interactions:
B:R.109
Water bridges:
B:Y.80,
B:R.109,
B:N.112
NAG.15:
5
residues within 4Å:
Chain B:
I.281,
N.283,
S.311,
T.312,
R.558
5 PLIP interactions:
5 interactions with chain B
Hydrogen bonds:
B:N.283,
B:R.558
Water bridges:
B:N.283,
B:N.283,
B:N.283
2 x
6AJ:
2-({2-[(3R)-3-aminopiperidin-1-yl]-5-methyl-6,9-dioxo-5,6,7,9-tetrahydro-1H-imidazo[1,2-a]purin-1-yl}methyl)-4-fluorobenzonitrile(Non-covalent)
Wu, W.L. et al., Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. Acs Med.Chem.Lett. (2016)
